- 1. Name of the medicinal product
- 2. Qualitative and quantitative composition
- 3. Pharmaceutical form
- 4. Clinical particulars
- 4.1 Therapeutic indications
- 4.2 Posology and method of administration
- 4.3 Contraindications
- 4.4 Special warnings and precautions for use
- 4.5 Interaction with other medicinal products and other forms of interaction
- 4.6 Fertility, pregnancy and lactation
- 4.7 Effects on ability to drive and use machines
- 4.8 Undesirable effects
- 4.9 Overdose
- 5. Pharmacological properties
- 5.1 Pharmacodynamic properties
- 5.2 Pharmacokinetic properties
- 5.3 Preclinical safety data
- 6. Pharmaceutical particulars
- 6.1 List of excipients
- 6.2 Incompatibilities
- 6.3 Shelf life
- 6.4 Special precautions for storage
- 6.5 Nature and contents of container
- 6.6 Special precautions for disposal and other handling
- 7. Marketing authorisation holder
- 8. Marketing authorisation number(s)
- 9. Date of first authorisation/renewal of the authorisation
- 10. Date of revision of the text
- Legal category
AdultsEfient should be initiated with a single 60 mg loading dose and then continued at 10 mg once a day. In UA/NSTEMI patients, where coronary angiography is performed within 48 hours after admission, the loading dose should only be given at the time of PCI (see sections 4.4, 4.8 and 5.1). Patients taking Efient should also take ASA daily (75 mg to 325 mg).In patients with acute coronary syndrome (ACS) who are managed with PCI, premature discontinuation of any antiplatelet agent, including Efient, could result in an increased risk of thrombosis, myocardial infarction or death due to the patient's underlying disease. A treatment of up to 12 months is recommended, unless the discontinuation of Efient is clinically indicated (see sections 4.4 and 5.1).Patients ≥ 75 years oldThe use of Efient in patients ≥ 75 years of age is generally not recommended. If, after a careful individual benefit/risk evaluation by the prescribing physician (see section 4.4), treatment is deemed necessary in the patients age group ≥ 75 years, then following a 60 mg loading dose a reduced maintenance dose of 5 mg should be prescribed. Patients ≥ 75 years of age have greater sensitivity to bleeding and higher exposure to the active metabolite of prasugrel (see sections 4.4, 4.8, 5.1 and 5.2).
Patients weighing <60 kgEfient should be given as a single 60 mg loading dose and then continued at a 5 mg once-daily dose. The 10 mg maintenance dose is not recommended. This is due to an increase in exposure to the active metabolite of prasugrel, and an increased risk of bleeding in patients with body weight <60 kg when given a 10 mg once-daily dose, compared with patients ≥60 kg (see sections 4.4, 4.8 and 5.2).
Renal impairmentNo dose adjustment is necessary for patients with renal impairment, including patients with end-stage renal disease (see section 5.2). There is limited therapeutic experience in patients with renal impairment (see section 4.4).
Hepatic impairmentNo dose adjustment is necessary in subjects with mild to moderate hepatic impairment (Child-Pugh class A and B) (see section 5.2). There is limited therapeutic experience in patients with mild and moderate hepatic dysfunction (see section 4.4). Efient is contraindicated in patients with severe hepatic impairment (Child-Pugh class C).
Paediatric populationThe safety and efficacy of Efient in children below age 18 has not been established. No data are available.
Method of administrationFor oral use. Efient may be administered with or without food. Administration of the 60 mg prasugrel loading dose in the fasted state may provide most rapid onset of action (see section 5.2). Do not crush or break the tablet.
Bleeding riskIn the phase 3 clinical trial (TRITON), key exclusion criteria included an increased risk of bleeding; anaemia; thrombocytopaenia; a history of pathological intracranial findings. Patients with acute coronary syndromes undergoing PCI treated with Efient and ASA showed an increased risk of major and minor bleeding according to the TIMI classification system. Therefore, the use of Efient in patients at increased risk of bleeding should only be considered when the benefits in terms of prevention of ischaemic events are deemed to outweigh the risk of serious bleedings. This concern applies especially to patients: ≥75 years of age (see below). with a propensity to bleed (e.g., due to recent trauma, recent surgery, recent or recurrent gastrointestinal bleeding, or active peptic ulcer disease). with body weight <60 kg (see sections 4.2 and 4.8). In these patients the 10 mg maintenance dose is not recommended. A 5 mg maintenance dose should be used. with concomitant administration of medicinal products that may increase the risk of bleeding, including oral anticoagulants, clopidogrel, non-steroidal anti-inflammatory drugs (NSAIDs), and fibrinolytics.For patients with active bleeding for whom reversal of the pharmacological effects of Efient is required, platelet transfusion may be appropriate.The use of Efient in patients ≥75 years of age is generally not recommended, and should only be undertaken with caution after a careful individual benefit/risk evaluation by the prescribing physician indicates that benefits in terms of prevention of ischaemic events outweigh the risk of serious bleedings. In the phase 3 clinical trial these patients were at greater risk of bleeding, including fatal bleeding, compared to patients <75 years of age. If prescribed, a lower maintenance dose of 5 mg should be used; the 10 mg maintenance dose is not recommended (see sections 4.2 and 4.8).Therapeutic experience with prasugrel is limited in patients with renal impairment (including ESRD) and in patients with moderate hepatic impairment. These patients may have an increased bleeding risk. Therefore, prasugrel should be used with caution in these patients.Patients should be told that it might take longer than usual to stop bleeding when they take prasugrel (in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician. Bleeding Risk Associated with Timing of Loading Dose in NSTEMIIn a clinical trial of NSTEMI patients (the ACCOAST study), where patients were scheduled to undergo coronary angiography within 2 to 48 hours after randomization, a prasugrel loading dose given on average 4 hours prior to coronary angiography increased the risk of major and minor peri-procedural bleeding compared with a prasugrel loading dose at the time of PCI. Therefore, in UA/NSTEMI patients, where coronary angiography is performed within 48 hours after admission, the loading dose should be given at the time of PCI. (see sections 4.2, 4.8 and 5.1).
SurgeryPatients should be advised to inform physicians and dentists that they are taking prasugrel before any surgery is scheduled, and before any new medicinal product is taken. If a patient is to undergo elective surgery, and an antiplatelet effect is not desired, Efient should be discontinued at least 7 days prior to surgery. Increased frequency (3-fold) and severity of bleeding may occur in patients undergoing CABG surgery within 7 days of discontinuation of prasugrel (see section 4.8). The benefits and risks of prasugrel should be carefully considered in patients in whom the coronary anatomy has not been defined, and urgent CABG is a possibility.
Hypersensitivity including angioedemaHypersensitivity reactions including angioedema have been reported in patients receiving prasugrel, including in patients with a history of hypersensitivity reaction to clopidogrel. Monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised (see section 4.8).
Thrombotic Thrombocytopenic Purpura (TTP)TTP has been reported with the use of prasugrel. TTP is a serious condition and requires prompt treatment.
LactosePatients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Efient.
Effects of other medicinal products on EfientAcetylsalicylic acid: Efient is to be administered concomitantly with acetylsalicylic acid (ASA). Although a pharmacodynamic interaction with ASA leading to an increased risk of bleeding is possible, the demonstration of the efficacy and safety of prasugrel comes from patients concomitantly treated with ASA. Heparin: A single intravenous bolus dose of unfractionated heparin (100 U/kg) did not significantly alter the prasugrel-mediated inhibition of platelet aggregation. Likewise, prasugrel did not significantly alter the effect of heparin on measures of coagulation. Therefore, both medicinal products can be administered concomitantly. An increased risk of bleeding is possible when Efient is co-administered with heparin.Statins: Atorvastatin (80 mg daily) did not alter the pharmacokinetics of prasugrel and its inhibition of platelet aggregation. Therefore, statins that are substrates of CYP3A are not anticipated to have an effect on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation.Medicinal products that elevate gastric pH: Daily co-administration of ranitidine (an H2 blocker) or lansoprazole (a proton pump inhibitor) did not change the prasugrel active metabolite's AUC and Tmax, but decreased the Cmax by 14% and 29%, respectively. In the phase 3 clinical trial, Efient was administered without regard to co-administration of a proton pump inhibitor or H2 blocker. Administration of the 60 mg prasugrel loading dose without concomitant use of proton pump inhibitors may provide most rapid onset of action.Inhibitors of CYP3A: Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4 and CYP3A5, did not affect prasugrel-mediated inhibition of platelet aggregation or the prasugrel active metabolite's AUC and Tmax, but decreased the Cmax by 34% to 46%. Therefore, CYP3A inhibitors such as azol antifungals, HIV protease inhibitors, clarithromycin, telithromycin, verapamil, diltiazem, indinavir, ciprofloxacin, and grapefruit juice are not anticipated to have a significant effect on the pharmacokinetics of the active metabolite.Inducers of cytochromes P450: Rifampicin (600 mg daily), a potent inducer of CYP3A and CYP2B6, and an inducer of CYP2C9, CYP2C19, and CYP2C8, did not significantly change the pharmacokinetics of prasugrel. Therefore, known CYP3A inducers such as rifampicin, carbamazepine, and other inducers of cytochromes P450 are not anticipated to have significant effect on the pharmacokinetics of the active metabolite.
Effects of Efient on other medicinal productsDigoxin: Prasugrel has no clinically significant effect on the pharmacokinetics of digoxin.Medicinal products metabolised by CYP2C9: Prasugrel did not inhibit CYP2C9, as it did not affect the pharmacokinetics of S-warfarin. Because of the potential for increased risk of bleeding, warfarin and Efient should be co-administered with caution (see section 4.4).Medicinal products metabolised by CYP2B6: Prasugrel is a weak inhibitor of CYP2B6. In healthy subjects, prasugrel decreased exposure to hydroxybupropion, a CYP2B6-mediated metabolite of bupropion, by 23%. This effect is likely to be of clinical concern only when prasugrel is co-administered with medicinal products for which CYP2B6 is the only metabolic pathway, and have a narrow therapeutic window (e.g., cyclophosphamide, efavirenz).
PregnancyAnimal studies do not indicate direct harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). Because animal reproduction studies are not always predictive of a human response, Efient should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the foetus.
Breast-feedingIt is unknown whether prasugrel is excreted in human breast milk. Animal studies have shown excretion of prasugrel in breast milk. The use of prasugrel during breastfeeding is not recommended.
FertilityPrasugrel had no effect on fertility of male and female rats at oral doses up to an exposure 240-times the recommended daily human maintenance dose (based on mg/m2).
Summary of the safety profileSafety in patients with acute coronary syndrome undergoing PCI was evaluated in one clopidogrel-controlled study (TRITON) in which 6741 patients were treated with prasugrel (60 mg loading dose and 10 mg once daily maintenance dose) for a median of 14.5 months (5802 patients were treated for over 6 months, 4136 patients were treated for more than 1 year). The rate of study drug discontinuation due to adverse events was 7.2% for prasugrel and 6.3% for clopidogrel. Of these, bleeding was the most common adverse reaction for both drugs leading to study drug discontinuation (2.5% for prasugrel and 1.4% for clopidogrel).
Non-Coronary Artery Bypass Graft (CABG) related bleedingIn TRITON, the frequency of patients experiencing a Non-CABG-related bleeding event is shown in Table 1. The incidence of Non-CABG-related TIMI major bleeding, including life-threatening and fatal, as well as TIMI minor bleeding, was statistically significantly higher in subjects treated with prasugrel compared to clopidogrel in the UA/NSTEMI and all ACS populations. No significant difference was seen in the STEMI population. The most common site of spontaneous bleeding was the gastrointestinal tract (1.7% rate with prasugrel and 1.3% rate with clopidogrel); the most frequent site of provoked bleeding was the arterial puncture site (1.3% rate with prasugrel and 1.2% with clopidogrel). Table 1: Incidence of Non-CABG-related bleedinga (% Patients)
|TIMI major bleedingc||2.2||1.7||2.2||1.6||2.2||2.0|
|Requiring surgical intervention||0.3||0.3||0.3||0.3||0.1||0.2|
|Requiring transfusion (≥4 units)||0.7||0.5||0.6||0.3||0.8||0.8|
|TIMI minor bleedingf||2.4||1.9||2.3||1.6||2.7||2.6|
|Age||Prasugrel 10 mg||Clopidogrel 75 mg|
|≥75 years (N=1785)*||9.0% (1.0% fatal)||6.9% (0.1% fatal)|
|<75 years (N=11672)*||3.8% (0.2% fatal)||2.9% (0.1% fatal)|
|<75 years (N=7180)**||2.0% (0.1% fatal) a||1.3% (0.1% fatal)|
|Prasugrel 5 mg||Clopidogrel 75 mg|
|≥75 years (N=2060) **||2.6% (0.3% fatal)||3.0% (0.5% fatal)|
*TRITON study in ACS patients undergoing PCI
**TRILOGY-ACS study in patients not undergoing PCI (see 5.1):a 10 mg prasugrel; 5 mg prasugrel if <60 kg
Patients < 60 kgNon-CABG-related TIMI major or minor bleeding rates:
|Weight||Prasugrel 10 mg||Clopidogrel 75 mg|
|<60 kg (N=664)*||10.1% (0% fatal)||6.5% (0.3% fatal)|
|≥60 kg (N=12672)*||4.2% (0.3% fatal)||3.3% (0.1% fatal)|
|≥60 kg (N=7845)**||2.2% (0.2% fatal) a||1.6% (0.2% fatal)|
|Prasugrel 5 mg||Clopidogrel 75 mg|
|<60kg (N=1391)**||1.4% (0.1% fatal)||2.2% (0.3% fatal)|
*TRITON study in ACS patients undergoing PCI
**TRILOGY-ACS study in patients not undergoing PCI (see 5.1):a 10 mg prasugrel; 5 mg prasugrel if ≥75 years of age
Patients ≥60 kg and age <75 yearsIn patients ≥60 kg and age <75 years, Non-CABG-related TIMI major or minor bleeding rates were 3.6% for prasugrel and 2.8% for clopidogrel; rates for fatal bleeding were 0.2% for prasugrel and 0.1% for clopidogrel.
CABG-related bleedingIn the phase 3 clinical trial, 437 patients underwent CABG during the course of the study. Of those patients, the rate of CABG-related TIMI major or minor bleeding was 14.1% for the prasugrel group and 4.5% in the clopidogrel group. The higher risk for bleeding events in subjects treated with prasugrel persisted up to 7 days from the most recent dose of study drug. For patients who received their thienopyridine within 3 days prior to CABG, the frequencies of TIMI major or minor bleeding were 26.7% (12 of 45 patients) in the prasugrel group, compared with 5.0% (3 of 60 patients) in the clopidogrel group. For patients who received their last dose of thienopyridine within 4 to 7 days prior to CABG, the frequencies decreased to 11.3% (9 of 80 patients) in the prasugrel group and 3.4% (3 of 89 patients) in the clopidogrel group. Beyond 7 days after drug discontinuation, the observed rates of CABG-related bleeding were similar between treatment groups (see section 4.4).
Bleeding Risk Associated with Timing of Loading Dose in NSTEMIIn a clinical study of NSTEMI patients (the ACCOAST study), where patients were scheduled to undergo coronary angiography within 2 to 48 hours after randomization, patients given a 30 mg loading dose on average 4 hours prior to coronary angiography followed by a 30 mg loading dose at the time of PCI had an increased risk of non-CABG peri-procedural bleeding and no additional benefit compared to patients receiving a 60 mg loading dose at the time of PCI (see sections 4.2 and 4.4). Non-CABG- related TIMI bleeding rates through 7 days for patients were as follows:
|Adverse Reaction||Prasugrel Prior to Coronary Angiographya(N=2037)%||Prasugrel At time of PCIa(N=1996)%|
|TIMI Major bleedingb||1.3||0.5|
|Requiring surgical intervention||0.4||0.1|
|Requiring transfusion (≥4 units)||0.3||0.1|
|TIMI Minor bleedinge||1.7||0.6|
bAny intracranial haemorrhage or any clinically overt bleeding associated with a fall in haemoglobin ≥ 5 g/dL.
cLife-threatening is a subset of TIMI Major bleeding and includes the types indented below. Patients may be counted in more than one row.
eClinically overt bleeding associated with a fall in haemoglobin of ≥ 3 g/dL but <5 g/dL.
Tabulated summary of adverse reactionsTable 2 summarises haemorrhagic and non-haemorrhagic adverse reactions in TRITON, or that were spontaneously reported, classified by frequency and system organ class. Frequencies are defined as follows:Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1000 to < 1/100); rare (≥ 1/10,000 to <1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). Table 2: Haemorrhagic and Non-haemorrhagic adverse reactions
|System Organ Class||Common||Uncommon||Rare||Not Known|
|Blood and Lymphatic system disorders||Anaemia||Thrombocytopaenia||Thrombotic thrombocytopaenic purpura (TTP) -see section 4.4|
|Immune system disorders||Hypersensitivity including angioedema|
|Eye disorders||Eye haemorrhage|
|Respiratory, thoracic and mediastinal disorders||Epistaxis||Haemoptysis|
|Gastrointestinal disorders||Gastrointestinal haemorrhage||Retroperitoneal haemorrhage Rectal haemorrhage Haematochezia Gingival bleeding|
|Skin and subcutaneous tissue disorders||Rash Ecchymosis|
|Renal and urinary disorders||Haematuria|
|General disorders and administration site conditions||Vessel puncture site haematoma Puncture site haemorrhage|
|Injury, poisoning and procedural complications||Contusion||Post-procedural haemorrhage||Subcutaneous haematoma|
|History of TIA or stroke||Prasugrel||Clopidogrel|
|Yes (N=518)||6.5% (2.3% ICH*)||1.2% (0% ICH*)|
|No (N=13090)||0.9% ( 0.2% ICH*)||1.0% (0.3% ICH*)|
* ICH=intracranial haemorrhage.
Reporting of suspected adverse reactionsReporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via UK: www.mhra.gov.uk/yellowcard, or Ireland: IMB Phamacovigilance, Earlsfort Terrace, IRL - Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, www.imb.ie, firstname.lastname@example.org.
PharmacodynamicsPrasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets. Since platelets participate in the initiation and/or evolution of thrombotic complications of atherosclerotic disease, inhibition of platelet function can result in the reduction of the rate of cardiovascular events such as death, myocardial infarction, or stroke.Following a 60 mg loading dose of prasugrel, inhibition of ADP-induced platelet aggregation occurs at 15 minutes with 5 µM ADP and 30 minutes with 20 µM ADP. The maximum inhibition by prasugrel of ADP-induced platelet aggregation is 83% with 5 µM ADP and 79% with 20 µM ADP, in both cases with 89% of healthy subjects and patients with stable atherosclerosis achieving at least 50% inhibition of platelet aggregation by 1 hour. Prasugrel-mediated inhibition of platelet aggregation exhibits low between-subject (9%) and within-subject (12%) variability with both 5 µM and 20 µM ADP. Mean steady-state inhibition of platelet aggregation was 74% and 69% respectively for 5 µM ADP and 20 µM ADP, and was achieved following 3 to 5 days of administration of the 10 mg prasugrel maintenance dose preceded by a 60 mg loading dose. More than 98% of subjects had ≥20% inhibition of platelet aggregation during maintenance dosing.Platelet aggregation gradually returned to baseline values after treatment in 7 to 9 days after administration of a single 60 mg loading dose of prasugrel, and in 5 days following discontinuation of maintenance dosing at steady-state.Switching data: Following administration of 75 mg clopidogrel once daily for 10 days, 40 healthy subjects were switched to prasugrel 10 mg once daily with or without a loading dose of 60 mg. Similar or higher inhibition of platelet aggregation was observed with prasugrel. Switching directly to prasugrel 60 mg loading dose resulted in the most rapid onset of higher platelet inhibition. Following administration of a 900 mg loading dose of clopidogrel (with ASA), 56 subjects with ACS were treated for 14 days with either prasugrel 10 mg once daily or clopidogrel 150 mg once daily, and then switched to either clopidogrel 150 mg or prasugrel 10 mg for another 14 days. Higher inhibition of platelet aggregation was observed in patients switched to prasugrel 10 mg compared with those treated with clopidogrel 150 mg. In a study of 276 ACS patients managed with PCI, switching from an initial loading dose of 600 mg clopidogrel or placebo administered upon presentation to the hospital prior to coronary angiography to a 60 mg loading dose of prasugrel administered at the time of percutaneous coronary intervention, resulted in a similar increased inhibition of platelet aggregation for the 72 hour duration of the study.
Efficacy and Safety in Acute Coronary Syndrome (ACS)The phase 3 TRITON study compared Efient (prasugrel) with clopidogrel, both co-administered with ASA and other standard therapy. TRITON was a 13,608 patient, multi-centre international, randomised, double-blind, parallel group study. Patients had ACS with moderate to high risk UA, NSTEMI, or STEMI and were managed with PCI.Patients with UA/NSTEMI within 72 hours of symptoms or STEMI between 12 hours to 14 days of symptoms were randomised after knowledge of coronary anatomy. Patients with STEMI within 12 hours of symptoms and planned for primary PCI could be randomised without knowledge of coronary anatomy. For all patients, the loading dose could be administered any time between randomisation and 1 hour after the patient left the catheterisation lab. Patients randomised to receive prasugrel (60 mg loading dose followed by 10 mg once daily) or clopidogrel (300 mg loading dose followed by 75 mg once daily) were treated for a median of 14.5 months (maximum of 15 months with a minimum of 6 months follow-up). Patients also received ASA (75 mg to 325 mg once daily). Use of any thienopyridine within 5 days before enrolment was an exclusion criterion. Other therapies, such as heparin and GPIIb/IIIa inhibitors, were administered at the discretion of the physician. Approximately 40% of patients (in each of the treatment groups) received GPIIb/IIIa inhibitors in support of PCI (no information available regarding the type of GPIIb/IIIa inhibitor used). Approximately 98% of patients (in each of the treatment groups) received antithrombins (heparin, low molecular weight heparin, bivalirudin, or other agent) directly in support of PCI.The trial's primary outcome measure was the time to first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction (MI), or non-fatal stroke. Analysis of the composite endpoint in the All ACS population (combined UA/NSTEMI and STEMI cohorts) was contingent on showing statistical superiority of prasugrel versus clopidogrel in the UA/NSTEMI cohort (p<0.05).All ACS population : Efient showed superior efficacy compared to clopidogrel in reducing the primary composite outcome events as well as the pre-specified secondary outcome events, including stent thrombosis (see Table 3). The benefit of prasugrel was apparent within the first 3 days and it persisted to the end of study. The superior efficacy was accompanied by an increase in major bleeding (see sections 4.4 and 4.8). The patient population was 92% Caucasian, 26% female, and 39% ≥65 years of age. The benefits associated with prasugrel were independent of the use of other acute and long-term cardiovascular therapies, including heparin/low molecular weight heparin, bivalirudin, intravenous GPIIb/IIIa inhibitors, lipid-lowering medicinal products, beta-blockers, and angiotensin converting enzyme inhibitors. The efficacy of prasugrel was independent of the ASA dose (75 mg to 325 mg once daily). The use of oral anticoagulants, non-study antiplatelet medicinal products and chronic NSAIDs was not allowed in TRITON. In the All ACS population, prasugrel was associated with a lower incidence of CV death, non-fatal MI, or non-fatal stroke compared to clopidogrel, regardless of baseline characteristics such as age, sex, body weight, geographical region, use of GPIIb/IIIa inhibitors, and stent type. The benefit was primarily due to a significant decrease in non-fatal MI (see Table 3). Subjects with diabetes had significant reductions in the primary, and all secondary composite endpoints.The observed benefit of prasugrel in patients ≥ 75 years was less than that observed in patients <75 years. Patients ≥ 75 years were at increased risk of bleeding, including fatal (see sections 4.2, 4.4, and 4.8). Patients ≥ 75 years in whom the benefit with prasugrel was more evident included those with diabetes, STEMI, higher risk of stent thrombosis, or recurrent events.Patients with a history of TIA or a history of ischaemic stroke more than 3 months prior to prasugrel therapy had no reduction in the primary composite endpoint.
Table 3: Patients with Outcome Events in TRITON Primary Analysis
|Outcome Events||Prasugrel + ASA||Clopidogrel +ASA||Hazard Ratio (HR) (95% CI)||p-value|
|All ACS||(N=6813)%||(N=6795)%||0.812 (0.732, 0.902)||<0.001|
|Primary Composite Outcome EventsCardiovascular (CV) death, non-fatal MI, or non-fatal stroke||9.4||11.5|
|Primary Individual Outcome Events|
|CV death||2.0||2.2||0.886 (0.701, 1.118)||0.307|
|Non-fatal MI||7.0||9.1||0.757 (0.672, 0.853)||<0.001|
|Non-fatal stroke||0.9||0.9||1.016 (0.712, 1.451)||0.930|
|UA/NSTEMI Primary Composite Outcome Events||(N= 5044)%||(N=5030)%|
|CV death, non-fatal MI, or non-fatal stroke||9.3||11.2||0.820 (0.726, 0.927)||0.002|
|CV death||1.8||1.8||0.979 (0.732,1.309)||0.885|
|Non-fatal MI||7.1||9.2||0.761 (0.663,0.873)||<0.001|
|Non-fatal stroke||0.8||0.8||0.979 (0.633,1.513)||0.922|
|STEMIPrimary Composite Outcome Events||(N= 1769)%||(N=1765)%|
|CV death, non-fatal MI, or non-fatal stroke||9.8||12.2||0.793 (0.649, 0.968)||0.019|
|CV death||2.4||3.3||0.738 (0.497,1.094)||0.129|
|Non-fatal MI||6.7||8.8||0.746 (0.588,0.948)||0.016|
|Non-fatal stroke||1.2||1.1||1.097 (0.590,2.040)||0.770|
AbsorptionThe absorption and metabolism of prasugrel are rapid, with peak plasma concentration (Cmax) of the active metabolite occurring in approximately 30 minutes. The active metabolite's exposure (AUC) increases proportionally over the therapeutic dose range. In a study of healthy subjects, AUC of the active metabolite was unaffected by a high fat, high calorie meal, but Cmax was decreased by 49% and the time to reach Cmax (Tmax) was increased from 0.5 to 1.5 hours. Efient was administered without regard to food in TRITON. Therefore, Efient can be administered without regard to food; however, the administration of prasugrel loading dose in the fasted state may provide most rapid onset of action (see section 4.2).
DistributionActive metabolite binding to human serum albumin (4% buffered solution) was 98%.
MetabolismPrasugrel is not detected in plasma following oral administration. It is rapidly hydrolysed in the intestine to a thiolactone, which is then converted to the active metabolite by a single step of cytochrome P450 metabolism, primarily by CYP3A4 and CYP2B6, and to a lesser extent by CYP2C9 and CYP2C19. The active metabolite is further metabolised to two inactive compounds by S-methylation, or conjugation with cysteine.In healthy subjects, patients with stable atherosclerosis, and patients with ACS receiving Efient, there was no relevant effect of genetic variation in CYP3A5, CYP2B6, CYP2C9, or CYP2C19 on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation.
EliminationApproximately 68% of the prasugrel dose is excreted in the urine and 27% in the faeces, as inactive metabolites. The active metabolite has an elimination half-life of about 7.4 hours (range 2 to 15 hours).
Special PopulationsElderly: In a study of healthy subjects between the ages of 20 and 80 years, age had no significant effect on pharmacokinetics of prasugrel or its inhibition of platelet aggregation. In the large phase 3 clinical trial, the mean estimated exposure (AUC) of the active metabolite was 19% higher in very elderly patients (≥75 years of age) compared to subjects <75 years of age. Prasugrel should be used with caution in patients ≥ 75 years of age due to the potential risk of bleeding in this population (see sections 4.2 and 4.4). In a study in subjects with stable atherosclerosis, the mean AUC of the active metabolite in patients ≥75 years old taking 5 mg prasugrel was approximately half that in patients < 65 years old taking 10 mg prasugrel, and the antiplatelet effect of 5 mg was reduced but was non-inferior compared to 10 mg.Hepatic impairment: No dose adjustment is necessary for patients with mild to moderate impaired hepatic function (Child-Pugh class A and B). Pharmacokinetics of prasugrel and its inhibition of platelet aggregation were similar in subjects with mild to moderate hepatic impairment compared to healthy subjects. Pharmacokinetics and pharmacodynamics of prasugrel in patients with severe hepatic impairment have not been studied. Prasugrel must not be used in patients with severe hepatic impairment (see section 4.3).Renal impairment: No dosage adjustment is necessary for patients with renal impairment, including patients with end stage renal disease (ESRD). Pharmacokinetics of prasugrel and its inhibition of platelet aggregation are similar in patients with moderate renal impairment (GFR 30-<50 ml/min/1.73m2) and healthy subjects. Prasugrel-mediated inhibition of platelet aggregation was also similar in patients with ESRD who required haemodialysis compared to healthy subjects, although Cmax and AUC of the active metabolite decreased 51% and 42%, respectively, in ESRD patients. Body weight: The mean exposure (AUC) of the active metabolite of prasugrel is approximately 30 to 40% higher in healthy subjects and patients with a body weight of <60 kg compared to those weighing ≥60 kg. Prasugrel should be used with caution in patients with a body weight of <60 kg due to the potential risk of bleeding in this population (see section 4.4). In a study in subjects with stable atherosclerosis, the mean AUC of the active metabolite in patients <60 kg taking 5 mg prasugrel was 38% lower than in patients ≥60 kg taking 10 mg prasugrel, and the antiplatelet effect of 5 mg was similar to 10 mg.Ethnicity: In clinical pharmacology studies, after adjusting for body weight, the AUC of the active metabolite was approximately 19% higher in Chinese, Japanese, and Korean subjects compared to that of Caucasians, predominantly related to higher exposure in Asian subjects <60 kg. There is no difference in exposure among Chinese, Japanese, and Korean subjects. Exposure in subjects of African and Hispanic descent is comparable to that of Caucasians. No dose adjustment is recommended based on ethnicity alone.Gender: In healthy subjects and patients, the pharmacokinetics of prasugrel are similar in men and women.Paediatric population: Pharmacokinetics and pharmacodynamics of prasugrel have not been evaluated in a paediatric population (see section 4.2).
Tablet Core:Microcrystalline celluloseMannitol (E421)Croscarmellose sodiumHypromellose (E464)Magnesium stearate
Film-Coat:Lactose monohydrateHypromellose (E464)Titanium dioxide (E171)Triacetin (E1518) Iron oxide red (E172) [10 mg tablets only]Iron oxide yellow (E172) Talc
|EU/1/08/503/001||Efient 5mg - 14 film-coated tablets|
|EU/1/08/503/002||Efient 5mg - 28 film-coated tablets|
|EU/1/08/503/015||Efient 5mg - 30 film-coated tablets|
|EU/1/08/503/003||Efient 5mg - 30x1 film-coated tablet|
|EU/1/08/503/004||Efient 5mg - 56 film-coated tablets|
|EU/1/08/503/005||Efient 5mg - 84 film-coated tablets|
|EU/1/08/503/006||Efient 5mg - 90x1 film-coated tablet|
|EU/1/08/503/007||Efient 5mg - 98 film-coated tablets|
|EU/1/08/503/008||Efient 10mg - 14 film-coated tablets|
|EU/1/08/503/009||Efient 10mg - 28 film-coated tablets|
|EU/1/08/503/016||Efient 10mg - 30 film-coated tablets|
|EU/1/08/503/010||Efient 10mg - 30x1 film-coated tablet|
|EU/1/08/503/011||Efient 10mg - 56 film-coated tablets|
|EU/1/08/503/012||Efient 10mg - 84 film-coated tablets|
|EU/1/08/503/013||Efient 10mg - 90x1 film-coated tablet|
|EU/1/08/503/014||Efient 10mg - 98 film-coated tablets|
|Date of first authorisation:||25 February 2009|
|Date of latest renewal:||13 November 2013|
Eli Lilly and Company Limited
Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL
+44 (0)1256 775 858
+44 (0)1256 775 569
+44 (0)1256 315 000